Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) EPS (Weighted Average and Diluted) (2020 - 2025)

Historic EPS (Weighted Average and Diluted) for KalVista Pharmaceuticals (KALV) over the last 3 years, with Q2 2025 value amounting to -$0.99.

  • KalVista Pharmaceuticals' EPS (Weighted Average and Diluted) rose 747.66% to -$0.99 in Q2 2025 from the same period last year, while for Apr 2025 it was -$3.77, marking a year-over-year decrease of 8823.43%. This contributed to the annual value of -$3.69 for FY2025, which is 718.43% down from last year.
  • KalVista Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to -$0.99 in Q2 2025, which was up 747.66% from -$0.87 recorded in Q3 2024.
  • In the past 5 years, KalVista Pharmaceuticals' EPS (Weighted Average and Diluted) registered a high of -$0.84 during Q1 2024, and its lowest value of -$1.07 during Q2 2024.